Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ACELYRIN Inc SLRN

Healthcare Biotechnology
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications... see more

Recent & Breaking News (NDAQ:SLRN)

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 25, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 24, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Acelyrin, Inc. - SLRN

Newsfile September 23, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire September 22, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acelyrin, Inc. - SLRN

PR Newswire September 21, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 21, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 19, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 18, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 17, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Acelyrin, Inc. - SLRN

Newsfile September 15, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire September 15, 2023

SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 14, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 13, 2023

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire September 12, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile September 12, 2023

ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

GlobeNewswire September 11, 2023

ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

GlobeNewswire September 6, 2023

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire August 14, 2023

ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023

GlobeNewswire August 7, 2023

ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer 

GlobeNewswire July 18, 2023